- ISIN
- US28658R1068
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Aug 10, 2021
Highlights
- Market Cap
- $811.39M
- Enterprise Value
- $803.78M
- EPS (TTM)
- -$0.78
- Gross Profit (TTM)
- -$106.00K
- EBITDA (TTM)
- -$55.93M
- Year Range
- $1.54 - $14.42
- Target Price
- $18.71
- ROA (TTM)
- -34.65%
- ROE (TTM)
- -35.65%
- Avg. Volume (1M)
- 1M
- Avg. Volume Value (1M)
- $15.17M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CLYM Performance Chart
Climb Bio Inc (CLYM) is up 197.5% since the beginning of the year. At $12 per share, CLYM is trading 17.4% below its 52-week high of $14.
Loading charts...
Compare this symbol against anything
Returns By Period
Climb Bio Inc (CLYM) has returned 197.50% so far this year and 720.69% over the past 12 months.
Climb Bio Inc
- 1D
- -1.49%
- 1M
- -7.75%
- 6M
- 166.22%
- YTD
- 197.50%
- 1Y
- 720.69%
- 3Y*
- 62.17%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -6.07%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
CLYM Monthly Returns History
Based on dividend-adjusted daily data since Aug 10, 2021, CLYM's average daily return is +0.20%, while the average monthly return is +3.63%. At this rate, an investment would double in approximately 1.6 years.
Historically, 43% of months were positive and 57% were negative. The best month was Apr 2024 with a return of +158.8%, while the worst month was Apr 2022 at -62.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.
On a daily basis, CLYM closed higher 48% of trading days. The best single day was Apr 11, 2024 with a return of +71.5%, while the worst single day was Apr 25, 2022 at -55.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 11.75% | 59.96% | -4.20% | 29.64% | 23.42% | 18.98% | -8.74% | 197.50% | |||||
| 2025 | 5.56% | -23.68% | -15.86% | 9.84% | -11.94% | 5.08% | 12.90% | 59.29% | -9.87% | 1.99% | -7.80% | 111.64% | 122.22% |
| 2024 | -5.19% | 6.64% | 0.37% | 158.76% | 8.74% | -7.78% | 16.60% | -15.68% | -27.18% | -24.85% | -15.56% | -44.27% | -33.33% |
| 2023 | -4.63% | 1.71% | -18.54% | 8.28% | -7.01% | -4.11% | -4.29% | -1.12% | -0.75% | 0.00% | -2.66% | 5.47% | -26.43% |
| 2022 | -13.58% | -0.33% | -6.88% | -62.34% | 21.20% | -21.15% | 5.30% | -3.77% | 5.56% | 1.24% | -21.71% | 43.36% | -64.91% |
| 2021 | 58.09% | -30.01% | -3.11% | -17.39% | -27.31% | -35.63% |
Benchmark Metrics
Climb Bio Inc has an annualized alpha of 49.41%, beta of 0.87, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since August 10, 2021.
- This stock participated in 67.62% of S&P 500 Index downside but only 13.76% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 49.41%
- Beta
- 0.87
- R²
- 0.02
- Upside Capture
- 13.76%
- Downside Capture
- 67.62%
Return for Risk
Risk / Return Rank
CLYM ranks 99 for risk / return — above 99% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Climb Bio Inc (CLYM) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CLYM | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +6.32 | ||
| Sortino ratioReturn per unit of downside risk | +3.17 | ||
| Omega ratioGain probability vs. loss probability | 1.59 | 1.25 | +0.34 |
| Calmar ratioReturn relative to maximum drawdown | 22.36 | 2.00 | +20.35 |
| Martin ratioReturn relative to average drawdown | 57.41 | 8.49 | +48.92 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Climb Bio Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Climb Bio Inc was 96.05%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Climb Bio Inc drawdown is 58.41%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-96.05%Apr 2025 | 3y 7mo | — | 4y 10moSep 2021 - now | 2025 selloff2025 |
-29.96%Aug 2021 | 1d | 12d | 13dAug 2021 - Aug 2021 | — |
-8.25%Aug 2021 | 1d | 7d | 7dAug 2021 - Sep 2021 | — |
-2.15%Aug 2021 | 1d | 1d | 1dAug 2021 - Aug 2021 | — |
Drawdown Indicators
| CLYM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.05% | -56.78% | -39.27% |
Max Drawdown (1Y)Largest decline over 1 year | -33.87% | -9.10% | -24.77% |
Max Drawdown (3Y)Largest decline over 3 years | -88.92% | -18.90% | -70.02% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -58.41% | -1.58% | -56.83% |
Average DrawdownAverage peak-to-trough decline | -80.94% | -10.70% | -70.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.16% | 2.14% | +11.02% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Climb Bio Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Climb Bio Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CLYM in comparison with other companies in the Biotechnology industry. Currently, CLYM has a P/B value of 5.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CLYM
Add Climb Bio Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CLYM